XM does not provide services to residents of the United States of America.
A
A

ABInbev

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Brazilian Brewer Ambev To Invest 150 Million Reais To Expand Capacity Of Premium Brands At Its Anapolis Plant - Statement

BRIEF-Brazilian Brewer Ambev To Invest 150 Million Reais To Expand Capacity Of Premium Brands At Its Anapolis Plant - Statement April 12 (Reuters) - Ambev SA ABEV3.SA : BRAZILIAN BREWER AMBEV TO INVEST 150 MILLION REAIS TO EXPAND CAPACITY OF PREMIUM BRANDS AT ITS ANAPOLIS PLANT - STATEMENT Source text for Eikon: [ID:] Further company coverage: ABEV
A

Corona beer maker Constellation Brands forecasts annual profit above estimates

Corona beer maker Constellation Brands forecasts annual profit above estimates April 11 (Reuters) - Constellation Brands STZ.N forecast annual profit above Wall Street expectations on Thursday, banking on resilient demand for its core beer brands despite sticky inflation. Demand across the company's beer brands like Modelo Especial and Pacifico remained strong as consumers stretched their budgets even though living expenses persistently rise.
A
M

Essilorluxottica, Remy Cointreau, Scout24

EUROPE RESEARCH ROUNDUP-Essilorluxottica, Remy Cointreau, Scout24 April 9 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Essilorluxottica, Remy Cointreau and Scout24, on Tuesday. HIGHLIGHTS * Burberry BRBY.L : Bernstein cuts target price to 1384p from 1402p * Essilorluxottica SA ESLX.PA : HSBC cuts to hold from buy * Remy Cointreau RCOP.PA : Jefferies cuts target price to EUR 120 from EUR 130 * Renault RENA.PA : Barclays raises to
A
A
B
B
B
C
H
I
K
K
K
L
L
L
M
N
O
P
R
R
S
S
S
T
T
T
U
V
A
A
J
J
M

Ben & Jerry’s rocky ESG road bucks vanilla trends

RPT-BREAKINGVIEWS-Ben & Jerry’s rocky ESG road bucks vanilla trends The author is a Reuters Breakingviews columnist. The opinions expressed are his own. By Jeffrey Goldfarb NEW YORK, April 4 (Reuters Breakingviews) - The world’s most popular ice cream flavor is vanilla. Corporate boards increasingly prefer it, too, judging by their changing tastes for environmental, social and governance matters.
A
U

AstraZeneca, Carl Zeiss Meditec, Luceco

EUROPE RESEARCH ROUNDUP-AstraZeneca, Carl Zeiss Meditec, Luceco April 5 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including AstraZeneca, Carl Zeiss Meditec and Luceco, on Friday. HIGHLIGHTS * AstraZeneca AZN.L : HSBC raises target price to 12,950p from 12,150p * Carl Zeiss Meditec AG AFXG.DE : JP Morgan raises target price to EUR 70 from EUR 59 * Ipsen SA IPN.PA : RBC raises target price to EUR 127 from EUR 124 * Luceco Plc LUCEL.L : P
A
A
A
B
B
C
E
G
H
I
K
S
S
S
S
W
A
A
A
A
A
A
B
D
S
U
Z

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.